^
FGFR1 rearrangement + Chr t(8;13)
T Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Resistant: C4 – Case Studies
Blood - 2 weeks
CD38 expression
T Acute Lymphoblastic Leukemia
isatuximab-irfc
Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide oral + etoposide oral + nelarabine
Sensitive: A2 - Guideline
No biomarker
T Acute Lymphoblastic Leukemia
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase
Sensitive: A2 - Guideline
TP53 mutation
T Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C1 - Off-label
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
FBXW7 mutation
T Acute Lymphoblastic Leukemia
prednisone
Resistant: C3 – Early Trials
HGF-L
T Acute Lymphoblastic Leukemia
mogamulizumab
Resistant: C3 – Early Trials
NOTCH1 L1574Q
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 V1577E
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 L1600Q
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 L1585R
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 V1577A
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 L1600P
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 L1574P
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 F1592S
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
NOTCH1 F1592C
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
JAK3 mutation
T Acute Lymphoblastic Leukemia
tofacitinib
Resistant: C4 – Case Studies
SET-NUP214 fusion
T Acute Lymphoblastic Leukemia
ADE
Sensitive: C4 – Case Studies
MEF2C overexpression
T Acute Lymphoblastic Leukemia
ABT-737
Sensitive: D – Preclinical
PAK2 overexpression
T Acute Lymphoblastic Leukemia
FRAX597 + PF-3758309
Sensitive: D – Preclinical
MCL1 underexpression
T Acute Lymphoblastic Leukemia
venetoclax + BI 6727
Sensitive: D – Preclinical
MYC underexpression
T Acute Lymphoblastic Leukemia
venetoclax + BI 6727
Sensitive: D – Preclinical
CCND3 deletion
T Acute Lymphoblastic Leukemia
palbociclib
Sensitive: D – Preclinical
JAK3 M511I
T Acute Lymphoblastic Leukemia
tofacitinib XR
Sensitive: D – Preclinical
JAK3 M511I
T Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
CB-839
Sensitive: D – Preclinical
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
IACS-010759
Sensitive: D – Preclinical
BCL2L1 underexpression
T Acute Lymphoblastic Leukemia
venetoclax + BI 6727
Sensitive: D – Preclinical
PRC2 mutation
T Acute Lymphoblastic Leukemia
JQ-1
Sensitive: D – Preclinical
PCDHB15 overexpression
T Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
NUP214-ABL1 rearrangement
T Acute Lymphoblastic Leukemia
dasatinib
Sensitive: D – Preclinical
TCRB-LCK translocation
T Acute Lymphoblastic Leukemia
dasatinib
Sensitive: D – Preclinical
RPL10 R98S
T Acute Lymphoblastic Leukemia
venetoclax
Sensitive: D – Preclinical
NT5C2 R367Q
T Acute Lymphoblastic Leukemia
mercaptopurine
Resistant: D – Preclinical